Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Clascoterone · Winlevi, CB-03-01

Small molecule · Antagonist of androgen receptor (AR) · developed by Sun Pharm

Approved FDA, Aug 2020
1 Registered trials

What is Clascoterone?

Clascoterone is a topical androgen receptor inhibitor applied to the skin. It is studied in androgenetic alopecia, where it is applied twice daily to balding areas of the scalp.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Winlevi, CB-03-01
Drug type
Small molecule
Targets
androgen receptor (AR)
Mechanism
Antagonist of androgen receptor (AR)
Therapy area
Dermatology
Developer
Sun Pharm
In trials of
ICLR
FDA status
Approved as Winlevi (August 26, 2020), NDA213433 · FDA label
UNII
XN7MM8XG2M

✅ FDA-approved uses

From the indications section of the FDA label (version of Jan 2, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05910450 Phase 3 Alopecia, Androgenetic Completed ICLR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alopecia, Androgenetic

Other drugs acting on AR

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.